Company Profile
BioNTech
— The first company to win an mRNA approval is shifting toward cancer treatments combining antibodies and ADCs
BioNTech is a COVID vac、 "Comirnaty" jointly developed with Pfizer.First approval as a medicine using mRNA. However, the subsequent sales will be reduced.Net loss of 113,610 millionComment In the end of June 2026€16 billionIn this fund Double specific antibody (co-developed with Bristol Myers Squibb), antibody drug complex (ADC), personalized mRNA cancer immunotherapy, etc. 2025 acquired CureVac of the same mRNA company. In this article, this company isWhat to do with mRNA and its carrier (LNP · lipoplex), and what to doHome We will organize the annual report (Form 20-F), quarter report (Form 6-K) submitted to the US SEC and the official announcement of the company.
- Viontech in 30 seconds and standing position in drug discovery and DDS
- About logo and company name
- Where is this company in the world of drug discovery and DDS?
- Size of the company (supporting reduction of COVID vac s with financial strength)
- Drug discovery and DDS resources
- Past Initiatives
- Future plans
- What is DDS?
- Collaboration mapping of drug discovery and DDS
- Technologies, Products and Services
- The risk of this company
- Glossary/Source/Ins ment and Source Response Table
1. Viontech in 30 seconds and standing position in drug discovery and DDS
(Multiple modalities)mRNA, antibody, ADC, cell therapy
Businesses related to drug discovery and DDS are largePharmaceutical Company / Biotech / Contract Development Manufacturing (CDMO・CRO)3 types. BioNTechDrug discovery biotechModerna of the same mRNA companyNot bet only mRNA FactsHome 20-F explains its technology as a platform for mRNA immunotherapy and protein medicine (monocrone antibody, double-specific antibody, and ADC). Main axisCancerIt is stated that it is written in. Most of the late items in the cancer areaAntibody and ADCAnd most of them were introduced and acquired from other companies. In other words, BioNTech is known as a company of mRNA, but as of 2026, it is Using COVID vaccine funds, we are trying to change to a cancer treatment company that combines antibody, ADC and mRNA.Comment
2. Logo and company name
BioNTech trademark In this article, we do not reproduce the generated image.
Images posted on the header of the official websiteHome img/biontech_logo.svg Contact Us
Note: Company name BioNTech SE "N" and "T" are upper case. Founded in 2008 as Petersberg 91 V AG, renamed BioNTech AG in the same year. In Japanese, it is often referred to as "Biontec". Joint product name with Pfizer ComirnatyComment
Official Site:https://www.biontech.com/int/en/home.html3. Where is this company in the world of drug discovery and DDS?
TypeDrug discovery biotechand handle modalitiesmRNA (LNP and lipoplex), double-specific antibody, ADC, cell therapyContact Us FactsHome The 20-F patent chapter contains two types of mRNA carriers. Used for in ious diseases vac sLipid nanoparticles (LNP)Used for cancer immunotherapy (iNeST of individualization, FixVac of ready-made products)RepoplexComment For the same mRNADDSThe technical characteristics of this company. The related basics are handled by the technical commentary "mRNA", "lipid nanoparticles", "antibody medicine and ADC".
4. Scope of the company (supporting the reduction of COVID vac s with financial strength)
The number is the disclosure of the company by international accounting standards (IFRS), and the unit is € million Facts。
| Indicator (Million Euro) | FY2023 | FY2024 | FY2025 | January to June 2026 |
|---|---|---|---|---|
| Sales | 3,819.0 | 2,751.1 | 2,869.9 | 223.7 |
| COVID Vac s | ―(No translation to the source of this article) | 2,432.1 | 1,995.3 | 118.8 |
| BMS | ― | ― | 613.0 | ― |
| R&D expenses | 1,783.1 | 2,254.2 | 2,104.9 | 1,108.0 |
| Net income (loss) | 930.3 | ▲665.3 | ▲1,136.1 | ▲1,352.7 |
| December 31, 2025 | June 30, 2026 | |
|---|---|---|
| Cash equivalents + securities investment | Approx. 1.7 billion euro | EUR 166.4 billion |
| (full-time conversion) | 7,807 (including 1,310 doctorate) CureVac (including 664 people) | Not specified in quarterly reports |
| Clinical Programs for Cancer Areas | 16 programs, 2nd and 3rd phase test 25 | 14 Pivotal Tests |
Comirnaty's sales are on BioNTech's profit and loss statementsNot in fullHome Pfizer sells the region as described in 20-FBioNTech's share of the total revenue of partnerscalculated as " FactsHome Therefore, the number of "COVID vac " above is not the market size of the vac or the sales amount. The sales of 2025 exceeded the previous year.T lead income €613 millionCOVID vac。 itself is reduced by 18%. 2026 sales forecast€16 Billion to €19 Billionlowered to As of March, EUR 20 billion to € 23 billion Undetermined / Future。
5. Drug discovery and DDS resources
| Resource Types | ||
|---|---|---|
| Person | Full-time conversion7,807 people(December 31, 2025). 2,634 business operations including 1,050 clinical development, 1,497 research and pre ical, and manufacturing. 6,317 European, 688 North America, 622 Asian and Australian, 180 African | Facts |
| People (Research and manufacturing base) | Head Office Mainz (East Wing, over 300 mRNAs), Marburg (about 450 people), Ider-Overstein BioNTech IMFS (about 500 people), Berlin (peptides), China's Zhuhai/Nantong, Rwanda Kigali (under construction), Melbourne, Australia (under construction) | Facts |
| Gold (R&D expenses) | FY2025 €24.9 millionHome 2026 is expected to pay €20 billion to €23 billion after adjustment | Facts |
| Gold (Manufacturing Equipment) | In 2025, we started to integrate and adjust our bases. Year 2026With al from multiple manufacturing sitesDecided the total cost of €6,890 million, including facilities at Marburg and Ida-Overstein. | Facts |
| Biotheus(completed in February 2025, €77.8 million in advance)CureVac(December 2025, stock exchange) complements the ability to design, deliver and manufacture mRNA. Insta | Facts | |
| License | 3 ADCs from DualityBio (HER2, B7H3, TROP2, 2023), Anti-CTLA-4 antibody from OncoC4 ($2 billion prepaid). For LNP, Ac)as is licensed under the patent of University of Pennsylvania (via MRT/CellScript) | Facts |
| Contact Us | BMS(pumitamig),mitntech(mRNA iNeST), Pfizer(COVID vac)), RNAnmab(antibody), Regeneron(BNT111 clinical trial) | Facts |
| University and Public Funds | TRON, University of Pennsylvania, Gates Foundation, CEPI, La Trobe University | Facts |
BioNTech’s research and development costsHow much is used for mRNA, antibody, and ADC?not disclosed Undetermined / FutureHome Financial results for the first half of the year of 2026 are the factors to push the R&D expensespumitamig andgotistobartIn of intangible assets and CureVac. There is no breakdown of the amount,Antibody effects are transferred to the antibody sidecan be read from this explanation.
6. Past Initiatives
| Time | Home | |
|---|---|---|
| Year 2008 | Established in June and renamed to BioNTech AG in December | A company launched by researchers in immunotherapy |
| Year 2009 | BioNTech IMFS became a wholly owned subsidiary. GMP manufacturing license for mRNA in 2011 | Production from early stages |
| September 2016 | Partnership between Genentech and iNeSTHome Prepaid and Short-Term Milestones: US$3 billion | Joint vac for individualized cancer |
| Year 2018 | Acquisition of iNeST manufacturing license at East Wing in Mainz (June) | Started manufacturing mRNA per patient. Over 1,700 b |
| Year 2020 | Partnership between Pfizer and COVID vaccineHome $72.5 million in prepaid, $113 million in Pfizer shares, half of development costs and total revenue | The world's first mRNA drug approval |
| March 2021 | Marburg Plant acquired COVID vaccine solution manufacturing approval from vaccine | A factory that can make up a maximum of 30 billion times a year |
| 2023 year | DualityBio and ADC 3 items | Full-scale entry into ADC in the cancer area |
| February 2025 | Completed Biotheus acquisitionPD-L1×VEGF-A double-specific antibody pumitamig | Securing late candidates |
| June 2025 | BMS and pumitamig co-development agreementHome $15 billion in advance, $20 billion in fixed payouts by 2028, $76 billion in milestones, | Separate costs and risks with majors |
| August 2025 | COVID vac for LP.8.1 approved by FDA and EU | The composition has been updated once a year |
| December 2025 | Acquisition of CureVac in Stock Exchange(completed 15 December, acquired the remaining shares in January 2026) | Compensating for the design, delivery and manufacturing capability of mRNA |
| March 2026 | Co-founder Mr. Sha and Mr. TuereyIndependent new companyAnnouncement of the establishment plan. Consultation in the direction of the next generation mRNA rights and technology | Cutting the next generation mRNA from the body |
| Year 2026 | 6 pivotal tests (pumitamig 5 or ADC 1) Determines withdrawal from multiple manufacturing sites | Resources for the late development of cancer |
| July to August 2026 | XFG-compliant COVID vac。 approved by the European Commission (July) and FDA (August 27). Nominated Guido Oelkers (appointed by February 1, 2027) as the next CEO on August 3 | Enter the mating phase of management |
Major clinical trials (the subject matter of this article)
| Test | Phase | Main evaluation items | Published situations (at the point of comparison and evaluation) |
|---|---|---|---|
| BNT122-01（autogene cevumeran、NCT04486378） | Phase 2 ctDNA-positive colorectal cancer (stage II high risk/III) after surgery, about 327 people | DFS | ControlElapse observationHome The first intermediate analysis (approximately 9 months) exceeds the boundary of unevenness, but continues to test as data unmature. Final analysis postponed in 2027 |
| IMCODE001（autogene cevumeran、NCT03815058） | Phase 2 Un ed progressive malignant melanoma | Unexpected survival (PFS) | ControlPembrolizmab aloneHome Statis significant improvement of key evaluation itemsNot achieved(March 2025) |
| PRESERVE-003（gotistobart、NCT05671510） | Phase 3 Non-Pivotal Phase 1 87 non-small cell lung cancer with pre-treated treatment | Total survival (OS) | ControlDocetaxelHome In 25.4 months, OS median 18.5 months to 10.0 months (HR 0.56, no p=0.0295). The second stage of the Pibutar continues |
The results above are written about the company's announcement.This article does not recommend the choice of treatmentHome As of September 2026Unapproved Development ItemsHome Undetermined / Future。
7. Future plans
Pharmaceutical CompanyExpression of company and CEO no release
| Products | Home | Stage (as of September 2026) | The following sections of the company |
|---|---|---|---|
| pumitamig（BNT327） | Double specific antibody (PD-L1×VEGF-A) | 3rd phase 7 Pivotal | 8 Global Registration Tests by BMS and the end of 2026 Undetermined / Future |
| trastuzumab pamirtecan（BNT323） | ADC（HER2） | 2 Phase 3 | DualityBio and 2026 3rd phase analysis of milk cancer is Q4 2026 Undetermined / Future |
| elfetabart drozuntecan（BNT324） | ADC（B7-H3） | Developed (3rd phase, starting May 2026) | Docetaxel with castent-resistant prostate Undetermined / Future |
| gotistobart（BNT316） | Anti-CTLA-4 Antibody | Developed (3rd phase) | The first intermediate analysis of the second stage will be scheduled in 2026 Undetermined / Future |
| autogene cevumeran（BNT122） | Individualized mRNA (repoplex) | 2nd phase Colon cancer and pancreatic cancer | Final analysis of colorectal cancer test 2027 Undetermined / Future |
| XFG Comirnaty | mRNA＋LNP | U.S.-EU approval | 2026-2027 Season |
20-F・6-K Undetermined / Future。
Co-founderWhat mRNA technology and rights do you have?and its terms and conditions/with al manufacturing sitesList and Time/ CureVacHow to useProductsApproval timing and sales forecastResearch and development costs by modalities. "BioNTech's cancer treatment drug is EUR 250 million per year"
8. What is this company aiming for drug discovery and DDS?
This includes parts that the company does not directly state.Calculation in the range that can be read from primary informationand write with the basis.
| Read | Primary Information | |
|---|---|---|
| By 2030Pharmaceutical company with multiple approved products | Announcement of Financial Results and CEO Nominated Release “To the Company of Multiple Products by 2030” | Facts |
| Candidates for approvalAntibody and ADC instead of mRNAHome | The third phase is pumitamig・trastuzumab pamirtecan・elfetabart drozuntecan・gotistobart, and mRNA cancer immunotherapy stays in phase 2 | |
| mRNAAntibody effects are transferred to the antibody siderepositioned as | 20-F is a combination of “combination of heavy-duty compounds of mechanisms of action” as a pillar of the strategy, and the combination of pumitamig and mRNA cancer immunotherapy is described. | |
| Part of next-generation mRNA technologyGrow outside the body | Plan to contribute to next generation mRNA rights and technology to a new company led by the co-founder | |
| CureVacpatent and formulation technology of mRNAThe face is large | In the calculation of the acquisition price, EUR 630 million is deducted as the liquidation of existing relationships (contracts and non-contracts). Intangible assets acquired are mainly intellectual property rights and licenses | |
| Production NetworkReduce and repositionat the stage | Since 2025, we have decided to withdraw from multiple locations in the first half of 2026. | Facts |
According to 20-F note, BioNTech to CureVac shareholdersADS value of 10.11 million euroContact Us However, it was calculated as "acquisition consideration"€90 millionthe difference€30 millionHome It is separated from corporate bonds as "cleaning existing relationships" FactsHome The breakdown is €418,890 million in unpaid balances based on contractual relationships and €1,140 million in unpaid relationships. 20-F refers to Note 18 for non-contract relationships, and Note 18 describes the history of CureVac Proceedings, which was prosecuting BioNTech in Comirnaty’s patent infringement in July 2022. This paper is for this acquisition.Complementation of mRNA technology and consolidate patent relationships within one companyRead the meaning Undetermined / FutureHome However, the company itself explains the purpose of acquisition as "completion of the ability and technology of design, delivery and manufacturing of mRNA" and does not write patent arrangement.
9. Collaboration mapping of drug discovery and DDS
10. Technologies, Products and Services
Approved products
| Products | Main approval (country, type, time) | |
|---|---|---|
| Comirnaty(BNT162b2) | COVID-19 vac enclosed by modifier nucleotide mRNA in LNP. Joint development with Pfizer | Approval and emergency use permission in more than 180 countries and regions as of March 2026. Over 50 billion times LP.8.1 version approved by the FDA in August 2025. The European Commission, in July 2026FDA on August 27, 2026approval (high-risk persons over 65 years old, 5 to 64 years old) |
Technical base: 4 types of "carryers" and multiple modalities
| Technology | 20-F Description | Used Items |
|---|---|---|
| Structure of mRNA | Patent applications such as 5' cap, 3' non-translation area, poly A chain, mRNA with reduced uracil content, modifier nucleotide | All mRNA items |
| Lipid nanoparticles (LNP) | Used for COVID vacs, RiboMab which makes antibody in the body with mRNA, and RiboCytokine which makes cytokines. Comirnaty's lipids and preparations are licensed from Ac as | Comirnaty |
| Repoplex | Preparation for cancer immunotherapy (iNeST, FixVac). Patents jointly held with BioNTech alone or TRON | autogene cevumeran、BNT111、BNT113 |
| Manufacture of individualized mRNA | MINEZ's East Wing is made by automated paperless mRNA for each patient. Over 1,700 b | autogene cevumeran |
| ADC Antibody | ADC is introduced fromalityalityBio. Manufacture of clinical antibody (original medicine and preparation) at Nandori factory in China | trastuzumab pamirtecan, pumitamig etc. |
| Cell Therapy and Peptides | Manufactured CAR-T cells in IMFS in less than 35 days. Syn) of peptides in Berlin (approximately twice the capacity of the new plant in September 2025) | BNT211 |
20-F Vac、LNPCancer immunotherapyRepoplexThe patent chapter clearly indicates that mRNA preparation is used. FactsHome In general, LNP is made by rapid mixing ionized fat, lipid, cholesterol, and PEG lipids from ethanol to water phase.Fine particles with mRNA insideComment Repoprex made in advanceA complex that combines positive liposom and mRNA electrolyHome The ratio of fat and mRNA (balance of charge) changes the particle surface charge and destination in the body. When viewed from the material side, the formerdesign and mixing process of lipidsThe latterManagement of liposome quality and mixing ratioIt is a game.
20-F, IMFS in addition to initial clinical preparationsReposom as a precursorIt is written that it is made. Making liposomes in-house reads the premise for managing lipoplex formulations on their own. BioNTechWe do not disclose the lipid composition of our lipoplex or LNPHome The general theory above is a general explanation of this article. It does not indicate the combination of BioNTech-specific. Undetermined / Future。
11. Risks that this company has
| Risks | ||
|---|---|---|
| reduced demand for COVID vacs | COVID vac) sales for the first half of 2026 is €1,880 million (euro 2,66 million). The company reduced sales forecast for 2026 due to the weakness of demand | Facts |
| Only one approved product | Only Comirnaty approved products as of September 2026. All cancer items are under development | Facts |
| Patent Litigation | Moderna’s European and English litigation continues. In July 2026, Arbutus/Genevant newly prosecuts Comirnaty patent infringement in Canada and European Unified Patent Court | Facts |
| Managing Director | CEO and Chief Medical Officer will move to a new company. After-sales CEO was appointed until February 2027. | Facts |
| Uncertainty of mRNA cancer immunotherapy | IMCODE001 has not received major evaluation items, and the colorectal cancer test has exceeded the boundary of unevenness in intermediate analysis (test continues) | Facts |
| Dependency on the product | Many of the late items are introduced and acquired from other companies, and the conditions of royalty and joint sales influence the profit | |
| Re ation of manufacturing network | decide the withdrawal from multiple locations and reduce equipment. Possibility of supplying or sending personnel during retraining |
12. Glossary
- mRNA
- design drawing to make protein into cells. In the vac , the antigen of the pathogen is created in cancer immunotherapy.
- LNP
- It contains mRNA internally, and it delivers it to cells from decomposition.
- Repoplex
- A complex that combines positive liposome and nucleic acid electroly. Nature changes with mixing ratio.
- iNeST
- BioNTech's personalized neo-antigen mRNA immunotherapy. Make each patient according to the mutations of the tumor.
- FixVac
- BioNTech's ready-made mRNA cancer immunotherapy. Aim for cancer antigens common to many patients.
- ADC
- A drug that connects antibodies with a linker and selectively delivers it to cancer cells.
- Double specific antibodies
- Antibodies that combine two different targets simultaneously. pumitamig joins PD-L1 and VEGF-A.
- Form 20-F／6-K
- Annual reports and extraordinary quarterly reports submitted by foreign companies listed in the US SEC.
Concept diagram of AI generation13. Source
- BioNTech SE Form 20-F for the) year ended December 31, 2025 Acquisition, sales, R&D, and net income of BMS, Pfizer,alityntech, DualityBio, OncoC4, sun, patent and license (Ac as, TRON, MRT/CellScript), Biotheus and CureVac. https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/bntx-20251231.htm
- BioNTech SE Quarterly Report for the three and six months ended June 30, 2026 (Form 6-K Attachment Exhibit 99.1, submitted August 4, 2026). Patent litigation, European approval of XFG-compliant vac。s, breakdown of sales, decision of withdrawal from manufacturing base, consultation status of new company, patent litigation. https://www.sec.gov/Archives/edgar/data/1776985/000177698526000055/bntxq22026ex991quarterlyre.htm
- BioNTech SE Financial Results for the Second Quarter of FY2026 (Form 6-K Attachment Exhibit 99.1, August 4, 2026). Earnings, R&D, Net Loss, Funds, Revised Outlook for 2026, Status of Pivotal Testing, Update of Pipeline, Targets for 2030 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000054/a991bntx_q22026pressreleas.htm
- BioNTech SE Press Release “BioNTech Announces Appointment of Odo Oelkers to Management Board as Chief Executive Officer” (Form 6-K, August 3, 2026). The transition to a new company of co-founder at the time of appointment and appointment of the next CEO. https://www.sec.gov/Archives/edgar/data/1776985/000177698526000051/a991biontechannouncesappoi.htm
- Pfizer Inc.／BioNTech SE Press Release “Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vac ” (Form 6-K, August 27, 2026). FDA approved and targeted for XFG-compliant vac。s. https://www.sec.gov/Archives/edgar/data/1776985/000177698526000059/a991bntx_covid-19xfgvarian.htm
- BioNTech SE／OncoC4, Inc. Press Release (Form 6-K), September 14, 2026. P。ERVE-003 1st stage of survival data (contrast docetaxel, 25.4 months). https://www.sec.gov/Archives/edgar/data/1776985/000177698526000063/a991260911_bntxwclcxgotist.htm
- ClinicalTrials.gov NCT04486378 (2nd phase of autogene cevumeran colon cancer). https://clinicaltrials.gov/study/NCT04486378
- BioNTech SE Official website (name and logo) https://www.biontech.com/int/en/home.html
14. Response table of claims and sources
| Content | ||
|---|---|---|
| Official name, head office location, listed market, established and renamed in 2008, and changed to SE in 2019 | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/bntx-20251231.htm |
| Policy that focuses on cancer with multiple technology platforms, 16 cancer domains, 2/3 phase 25 super | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/bntx-20251231.htm |
| Sales of 2023-2025, COVID vacs sales, investment income, R&D expenses, net income, net income, net income, and hand fund of the end of 2025 EUR 172 billion | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/bntx-20251231.htm |
| COVID vacs sales are calculated as the total profit of the partner | Facts | Source 1・2 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000055/bntxq22026ex991quarterlyre.htm |
| Sales, COVID vaccine sales, R&D expenses, net loss, retained funds at the end of June, pivotal test 14, 2026 target revision, target of 2030 | Facts | Source 3 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000054/a991bntx_q22026pressreleas.htm |
| 7,807 employees (full-time equivalent) and job titles and regional breakdowns | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/bntx-20251231.htm |
| Production base (Marburg IMFS, East Wing, Berlin, Zhuhai, Nanjing, Kigali, Melbourne) and personnel and capacity | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/bntx-20251231.htm |
| Decision on withdrawal from multiple manufacturing sites and losses in Marburg Ider-Overstein | Facts | Source 2 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000055/bntxq22026ex991quarterlyre.htm |
| Agreement with BMS (prepaid $15 billion, fixed pay $20 billion, milestone up to $76 billion, profit and loss halves) | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/bntx-20251231.htm |
| Pfizer・Genentech・DualityBio・OncoC4・Genesun | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/bntx-20251231.htm |
| Acquisition of Biotheus (prepaid €77.8 million) and acquisition of CureVac (equivalent to €10 million in stock, €4 trillion in acquisition, €6 trillion in existing relationships), and €6 trillion in July 2022 by CureVac | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/bntx-20251231.htm |
| LNP and lipoplex are used in conjunction with Ac, TRON, MRT, and CellScript licenses. | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/bntx-20251231.htm |
| Approval of Comirnaty approved countries, regions and shipments, and LP.8.1 supported versions | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/bntx-20251231.htm |
| XFG-compatible version of FDA approved (August 27, 2026) | Facts | Source 5 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000059/a991bntx_covid-19xfgvarian.htm |
| Interim analysis of autogene cevumeran colonic cancer test and postponement of final analysis, result of IMCODE001 | Facts | Source 1・7 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/bntx-20251231.htm |
| Pervive-003 1st stage OS (18.5 months to 10.0 months, HR 0.56, 25.4 months, 87 people) | Facts | Source 6 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000063/a991260911_bntxwclcxgotist.htm |
| Nominating the next CEO and moving to a new company | Facts | Source 4 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000051/a991biontechannouncesappoi.htm |
| Patent Litigation with Moderna Arbutus/Genevant | Facts | Source 2 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000055/bntxq22026ex991quarterlyre.htm |
| Drug discovery and DDS classification (pharmaceu company / drug discovery biotech / contract development manufacturing and research) | The calculation of this paper | This article. Company name is an example of a company handled by this series. |
| Difference between LNP and lipoplex | The calculation of this paper | General explanation by this article. BioNTech-specific formula not included |
| Under the technology and rights of the new company, the list and time of withdrawal bases, the expected approval period, the R&D expenses for modalities, the lipid composition of LNP and lipoprex | Undetermined / Future | Not specified in the source 1-6. No number of media and survey companies https://www.sec.gov/Archives/edgar/data/1776985/000177698526000055/bntxq22026ex991quarterlyre.htm |
| This approval candidate is based on antibody and ADC. | Interpre of this paper from the stage of each item of source 3 | |
| Read that mRNA is repositioned to the combination partner of antibody | Interpre of this paper from the description of the combination strategy of Source 1 | |
| Read to grow next generation mRNA outside the body | Interpre of this paper from the description of the new company of Source 1 and 4 | |
| Read that CureVac acquires a patent relationship | Interpre of this paper from accounting for acquisition of source 1 | |
| Risks related to dependency on the product and return of the production network | Interpre of this document from the affiliation structure of the source 1 and 2 and the description of the withdrawal of the base |
Last Updated:September 26, 2026/Troy Technical
All figures in this article are based on the legal disclosure document submitted by BioNTech SE to the US Securities and Exchange Commission (SEC) and the official announcement of the company, ClinicalTrials.gov. We do not use estimates and media-based numbers of survey companies. The "、ulation" section is an interpretation that the article reads from the primary information and is not an announcement of the company. This article is not medical advice.